PHARMA-DEKO PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.83 NGN | 0.00% |
|
0.00% | 0.00% |
Valuation
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 386.2 | 512 | 325.4 | 325.4 | 325.4 | 477.2 |
| Enterprise Value (EV) 1 | 390.7 | 449 | 337.7 | 334.2 | 230.3 | 456.4 |
| P/E ratio | -1.77 x | 40.6 x | -1.23 x | -1.16 x | -1.01 x | -6.84 x |
| Yield | 11.2% | 2.12% | - | - | - | - |
| Capitalization / Revenue | 0.35 x | 0.32 x | 0.32 x | 0.67 x | 0.71 x | 0.95 x |
| EV / Revenue | 0.36 x | 0.28 x | 0.33 x | 0.69 x | 0.5 x | 0.91 x |
| EV / EBITDA | -2.22 x | 4.86 x | -1.88 x | -1.19 x | -0.92 x | -10.4 x |
| EV / FCF | -0.76 x | 5.75 x | -10.4 x | -51.3 x | 0.51 x | -5.99 x |
| FCF Yield | -132% | 17.4% | -9.63% | -1.95% | 198% | -16.7% |
| Price to Book | 0.22 x | 0.29 x | 0.2 x | 0.25 x | 0.33 x | 0.36 x |
| Nbr of stocks (in thousands) | 216,942 | 216,930 | 216,932 | 216,930 | 216,930 | 216,932 |
| Reference price 2 | 1.780 | 2.360 | 1.500 | 1.500 | 1.500 | 2.200 |
| Announcement Date | 3/31/17 | 3/29/18 | 3/29/19 | 5/30/20 | 3/31/21 | 4/22/22 |
1NGN in Million2NGN
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,095 | 1,593 | 1,024 | 484.6 | 460.8 | 503.5 |
| EBITDA 1 | -176.3 | 92.36 | -179.3 | -281.1 | -250.9 | -43.76 |
| EBIT 1 | -223 | 35.18 | -255.2 | -360.4 | -321.9 | -111.6 |
| Operating Margin | -20.36% | 2.21% | -24.92% | -74.37% | -69.85% | -22.17% |
| Earnings before Tax (EBT) 1 | -208.5 | 39.32 | -256 | -276.5 | -324.1 | -68.49 |
| Net income 1 | -218.7 | 12.61 | -265.3 | -278.9 | -325.2 | -69.79 |
| Net margin | -19.97% | 0.79% | -25.91% | -57.55% | -70.57% | -13.86% |
| EPS 2 | -1.008 | 0.0581 | -1.220 | -1.290 | -1.490 | -0.3217 |
| Free Cash Flow 1 | -513.9 | 78.03 | -32.53 | -6.521 | 455.4 | -76.24 |
| FCF margin | -46.93% | 4.9% | -3.18% | -1.35% | 98.82% | -15.14% |
| FCF Conversion (EBITDA) | - | 84.49% | - | - | - | - |
| FCF Conversion (Net income) | - | 618.93% | - | - | - | - |
| Dividend per Share 2 | 0.2000 | 0.0500 | - | - | - | - |
| Announcement Date | 3/31/17 | 3/29/18 | 3/29/19 | 5/30/20 | 3/31/21 | 4/22/22 |
1NGN in Million2NGN
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 4.57 | - | 12.3 | 8.84 | - | - |
| Net Cash position 1 | - | 63 | - | - | 95.1 | 20.9 |
| Leverage (Debt/EBITDA) | -0.0259 x | - | -0.0687 x | -0.0314 x | - | - |
| Free Cash Flow 1 | -514 | 78 | -32.5 | -6.52 | 455 | -76.2 |
| ROE (net income / shareholders' equity) | -12.4% | 0.72% | -15.9% | -19.2% | -28.3% | -6.08% |
| ROA (Net income/ Total Assets) | -5.7% | 0.96% | -6.94% | -9.96% | -9.55% | -3.21% |
| Assets 1 | 3,840 | 1,317 | 3,821 | 2,799 | 3,407 | 2,177 |
| Book Value Per Share 2 | 8.020 | 8.030 | 7.330 | 6.050 | 4.550 | 6.030 |
| Cash Flow per Share 2 | 0.2100 | 0.2900 | 0.1700 | 0.0300 | 0.5000 | 0.1800 |
| Capex 1 | 270 | 59.6 | 14.5 | - | 0.71 | 26.1 |
| Capex / Sales | 24.63% | 3.74% | 1.41% | - | 0.15% | 5.18% |
| Announcement Date | 3/31/17 | 3/29/18 | 3/29/19 | 5/30/20 | 3/31/21 | 4/22/22 |
1NGN in Million2NGN
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 259K | |
| +18.71% | 44.35B | |
| +19.44% | 15.08B | |
| +19.49% | 14.37B | |
| +57.58% | 13.06B | |
| -0.05% | 6.79B | |
| -9.70% | 6.75B | |
| -8.87% | 5.73B | |
| +12.55% | 5.64B | |
| +4.00% | 4.66B |
- Stock Market
- Equities
- PHARMDEKO Stock
- Financials Pharma-Deko Plc
